• Police seek suspects in deadly birthday party shooting
  • Lawmakers launch inquires into U.S. boat strike
  • Nov. 29, 2025, 10:07 PM EST / Updated Nov. 30, 2025,…
  • Mark Kelly says troops ‘can tell’ what orders…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

Here's the biggest news you missed this weekend

admin - Latest News - November 2, 2025
admin
18 views 29 secs 0 Comments




Democrats have an early lead in next year’s battle for control of Congress amid an ongoing government shutdown, as more voters say President Donald Trump has not lived up to their expectations on several major issues that propelled him back to the White House in 2024, according to a new national NBC News poll



Source link

TAGS:
PREVIOUS
Train collides with truck hauling cars in Texas
NEXT
Savewith a NBCUniversal ProfileCreate your free profile or log in to save this articleNov. 2, 2025, 6:05 PM ESTBy Andrew GreifIn August, Jacksonville Jaguars kicker Cam Little teased that his leg was strong enough to break the NFL’s record.On Sunday, he did it for real. Little’s 68-yard field goal in the second quarter against Las Vegas — inside the Raiders’ domed stadium — broke the record by two yards, exceeding the 66-yard kick by Baltimore’s Justin Tucker that had stood in the record books since 2021.Little had shown such a kick was possible when he booted a 70-yard field goal during a preseason game in August. Because it was an exhibition, the kick did not officially count as a record. Between that kick and Sunday’s Week 9 record, however, Little had actually struggled to convert long kicks during his second NFL season, making just four of his eight attempts from 40-plus yards, including one of three from 50-plus.Little’s kick came amid a kicking renaissance in the NFL, where during the last two seasons kickers are making 50-plus yard field goals at a higher rate than any point in NFL history. One factor behind that rise is a new rule put in place this season that allowed teams to receive 60 “K-balls” — balls used exclusively by kickers — before the season began. Kickers can then work with those balls to break them in and make them as easy to kick, within the rules, as possible. Previously, teams would only be given three brand-new “K-balls” less than two hours before kickoff.Andrew GreifAndrew Greif is a sports reporter for NBC News Digital. 
Related Post
October 8, 2025
Savewith a NBCUniversal ProfileCreate your free profile or log in to save this articleOct. 8, 2025, 5:00 AM EDTBy Ryan J. ReillyWASHINGTON — Former FBI Director James Comey will appear in a federal court in Alexandria, Virginia, on Wednesday for his arraignment on charges brought after a public campaign by President Donald Trump to prosecute him.A federal grand jury in the Eastern District of Virginia indicted Comey, whom Trump fired during his first term in office, on two charges last month: making a false statement and obstruction of a congressional proceeding.Trump had posted just days earlier on his social media platform, calling on Attorney General Pam Bondi to charge Comey. “We can’t delay any longer,” he wrote.Special Report: Former FBI Director James Comey indicted on two counts16:17Comey, who was a registered Republican and served in the Justice Department during the George W. Bush administration, became the subject of Trump’s ire after he helped spark special counsel Robert Mueller’s investigation into Russian interference in the 2016 election.The Trump administration accuses Comey of lying to Congress about having authorized a third party to speak anonymously to the media about an FBI investigation. Comey told Congress in 2017 he did not authorize any leaks related to an investigation, and he told the Senate again in 2020, “I stand by the testimony.”Comey is expected to be presented with the charges and plead not guilty at Wednesday’s hearing, which begins at 10 a.m.The charges were filed after Trump successfully pressured the acting head of the U.S. Attorney’s Office for the Eastern District of Virginia to resign. Trump then named one of his former personal attorneys, Lindsey Halligan, to head the office, though she has no prosecutorial experience. And Halligan presented the case against Comey to a grand jury by herself, which is highly unusual and raised additional red flags about the merits of the case.Halligan sought three charges, but 12 or more of the grand jurors found that there was not probable cause to indict him on one of the charges. Most of the grand jurors found there was probable cause to charge Comey with making false statements to Congress and obstruction of a congressional proceeding.Comey is set to appear before U.S. District Judge Michael Nachmanoff. In addition to Halligan, two prosecutors from a separate U.S. attorney’s office in North Carolina — Nathaniel Lemons and Gabriel J. Diaz — were added to the case.No electronics are allowed in the Alexandria courthouse, meaning news about the arraignment may take a while to emerge.Trump has called for charges to be filed against other political foes since he began his second term, including New York Attorney General Letitia James and Sen. Adam Schiff, D-Calif.A group of former federal judges warned last week that the case against Comey presented a “grave danger” to the rights and liberties of every American as “President Donald Trump continues to corruptly abuse the power of his office by directing the United States Department of Justice and the Federal Bureau of Investigation to target his critics and his perceived political enemies for investigation and criminal prosecution.”Ryan J. ReillyRyan J. Reilly is a justice reporter for NBC News.
October 4, 2025
Oct. 3, 2025, 8:33 PM EDTBy Gary Grumbach and Dareh GregorianA federal judge on Friday ordered a hearing into whether the criminal case against Kilmar Abrego Garcia was the result of a “vindictive” prosecution, finding there’s “some evidence” that it was.In his 16-page ruling, U.S. District Judge Waverly Crenshaw in Tennessee noted that the investigation into Abrego was reopened shortly after he successfully challenged to the U.S. Supreme Court what the Trump administration acknowledged was his mistaken deportation to a prison in El Salvador.The investigation also came after numerous administration officials, including Attorney General Pam Bondi and Homeland Security Secretary Kristi Noem, repeatedly accused Abrego of being guilty of numerous crimes, and being a “gang member” and a “terrorist.” His lawyers and family members have repeatedly denied the claims.”Actual vindictiveness may be apparent based on the Executive Official Defendants’ and their subordinates’ statements about Abrego from the time he filed his Maryland lawsuit” challenging his deportation “through his arrest in this District,” the judge wrote.In his ruling granting Abrego’s request for a hearing on the vindictive prosecution claims, Crenshaw focused on comments that Bondi’s top deputy, Todd Blanche, made on Fox News the day of his June arrest on human trafficking charges, to which Abrego pleaded not guilty.”Strikingly, during a television interview Deputy Attorney General Blanche revealed that the government started ‘investigating’ Abrego after ‘a judge in Maryland . . . questioned’ the government’s decision, found that it ‘had no right to deport him,’ and ‘accus[ed] [the government] of doing something wrong,’” the judge wrote.“Deputy Attorney General Blanche’s remarkable statements,” Crenshaw wrote, “could directly establish that the motivations for Abrego’s criminal charges stem from his exercise of his constitutional and statutory rights to bring suit against the Executive Official Defendants, rather than a genuine desire to prosecute him for alleged criminal misconduct.”Watch: Kilmar Abrego Garcia reunites with family after release from federal custody01:13The judge, nominated to the bench by President Barack Obama, said Abrego’s claims also appear to be supported by the timing of the reopening of the criminal investigation, which had started as the result of a traffic stop in 2022 and was deemed to be closed in March of this year, before Abrego was deported. Abrego was released without charges after the 2022 stop.The investigation was reopened a week after Abrego’s win in the Supreme Court in April.”This timeline suggests that Abrego’s prosecution may stem from retaliation by the DOJ and DHS due to Abrego’s successful challenge of his unlawful deportation in Maryland,” the judge wrote.The judge ordered the government to turn over information and evidence being requested by Abrego and said he’ll hold a hearing after that.”After the parties conduct discovery, ‘[i]t may well be that no fire will be discovered under all the smoke[.]’ Indeed, the Government could produce evidence showing legitimate reasons for its prosecution of Abrego that are unrelated to his case in the District of Maryland,” he wrote.Representatives for the Department of Homeland Security and the Justice Department did not immediately respond to requests for comment Friday.Abrego, a Salvadoran national who, according to his lawyers, entered the U.S. illegally when he was 16 years old to escape gang violence, is trying to get the criminal charges against him dismissed.He also made a bid to reopen his petition for asylum, but an immigration judge rejected the request in a ruling Thursday. He has 30 days to appeal to the Board of Immigration Appeals.A different immigration judge had previously ruled in 2019 that he could not be deported to El Salvador, because he faced danger from a gang that targeted his family. U.S. Immigration and Customs Enforcement is seeking to deport him to Uganda or Eswatini.Gary GrumbachGary Grumbach is an NBC News legal affairs reporter, based in Washington, D.C.Dareh GregorianDareh Gregorian is a politics reporter for NBC News.Raquel Coronell Uribe contributed.
November 21, 2025
After meeting Mamdani, Trump says he would feel comfortable living in New York City
September 27, 2025
Sept. 27, 2025, 5:30 AM EDTBy Berkeley Lovelace Jr.For people who rely on certain prescription drugs, including weight loss, asthma and cancer medications, President Donald Trump’s post announcing 100% tariffs on foreign brand-name drugs offers little clarity on when — or if — medications might see price hikes. “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” Trump said on Truth Social late Thursday. “‘IS BUILDING’ will be defined as, ‘breaking ground’ and/or ‘under construction.’ There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”Experts say Trump’s post raises a lot of questions. Here are five major ones. What drugs will be impacted?Trump’s post doesn’t specify whether brand-name drugmakers with an existing U.S. plant would be exempt, whether that exemption would include all their products, or whether it would only be for the drugs manufactured at the U.S. site. Novo Nordisk and Eli Lilly, makers of the weight loss drugs Wegovy and Zepound, respectively, have announced plans to invest in U.S. manufacturing. But it’s unclear if their intent to invest will warrant an exemption. On Tuesday, Lilly announced plans for a $6.5 billion manufacturing facility in Houston that will produce Zepbound and its other GLP-1 drug, Mounjaro, following a recent commitment to build a $5 billion plant near Richmond, Virginia. Novo Nordisk, a Danish company, said in June it would spend $4.1 billion to construct a second GLP-1 fill-finish plant in Clayton, North Carolina.AstraZeneca, which makes the asthma drug Symbicort, also announced in July that it will invest $50 billion over the next five years to expand its research and development and manufacturing footprint in the U.S. Many other popular brand-name drugs, however, are primarily manufactured overseas, particularly in Europe, said Rena Conti, an associate professor at Boston University’s Questrom School of Business.Botox, made by Allergen, and the cancer drug Keytruda from drugmaker Merck are made in Ireland. (Keytruda’s manufacturing has increasingly moved to the United States in recent years, but it’s not clear if that would earn an exemption from Trump’s tariffs.)Others, including some for blood and lung cancers, as well as vaccines, are made in places like India and China, Conti said. “I think what’s most at risk here are branded products that come from China and India,” she said. The E.U. and Japan already have trade agreements in place that cover pharmaceuticals, she added, and it’s unclear whether the new tariff will supersede that. Will patients see prices increase?Only 1 in 10 of the prescriptions filled in the U.S. are for brand-name drugs; the vast majority are for generics, which are much cheaper and will not be affected by these tariffs. Whether patients see price increases will depend on how many drugmakers receive exemptions — and on whether companies choose to pass those costs on to patients at the pharmacy counter, said Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School. ​​“Ultimately, tariffs are taxes on patients,” Kesselheim said, “and to the extent that drug companies see increases in cost due to tariffs, they will pass those costs on to patients.”Some companies may decide not to pass the costs along. So far, the 15% tariffs on imports from the E.U. haven’t translated into big price hikes for U.S. patients, Conti noted. To be sure, a 100% tariff would be far more costly for a company. Price hikes may not start right away, as drugmakers find out whether they qualify for an exemption. There also might be a lag since U.S. law prevents drugmakers from increasing the price of drugs faster than inflation.“What if you’re doing updates to the plant you currently have? What if you’re planning a facility? Do those count?” Kesselheim said. “It’s all very ambiguous.”Some patients may not notice additional price hikes at all, given how costly brand-name drugs already are in the U.S., said Arthur Caplan, the head of the Division of Medical Ethics at NYU Langone Medical Center in New York City. “I can certainly predict that some patients will immediately feel price increases that will shock them on some of these drugs,” Caplan said.Could insurers absorb the costs?Insurers and middlemen, known as pharmacy benefit managers, could try to negotiate drugmakers or absorb some of the tariff-related costs, Caplan said.It’s more likely, however, that they’d pass it on to patients in the short term, potentially in the form of a larger copay, he said.It’s not only patients with private insurance that should be worried about price hikes, Kesselheim said. Those who get their drugs covered through government health programs could also see price increases.“The government is the largest purchaser of prescription drugs in the market, through Medicare, Medicaid and the VA, so it’s really the government or government payers that are going to see the largest impact on price increases,” he said. Will tariffs spur more U.S. drug manufacturing?It’s unlikely, Kesselheim said. The decision to build a plant “is a complicated and expensive one” that requires several regulatory hurdles and years of planning.Conti noted that by the time new manufacturing plants are completed, Trump would likely be out of office.“It is somewhere between two years and five years to get new production facilities built,” she said, “and it can be in the millions of dollars depending on whether the product that you’re making is a small molecule drug or a biologic.”Even putting money back into an existing plant isn’t quick.“If you want to switch a line or retool a factory to make a product, then we’re talking about somewhere between 18 to 36 months to do that,” Conti said, “because you have to show the U.S. regulator that you can make it at this factory at scale, and the product is what it says it is, or is high quality and meets the quality standards of the U.S.”In a statement, Alex Schriver, a spokesperson for the trade group the Pharmaceutical Research and Manufacturers of America, said “most innovative medicines prescribed in America are already made in America” and companies continue to invest in the U.S.“Tariffs risk those plans because every dollar spent on tariffs is a dollar that cannot be invested in American manufacturing or the development of future treatments and cures,” Schriver said. “Medicines have historically been exempt from tariffs because they raise costs and could lead to shortages.”What about shortages?If Trump keeps his focus solely on brand-name drugs, U.S. patients are unlikely to face shortages, Kesselheim said.“Their profits are just so, so far beyond this tariff cost that they could probably be OK or raise the prices of the drugs,” he said. “They would probably not stop production as a result.”But that excludes, he added, some smaller companies who may make niche brand-name products and may not have the resources to take on the extra costs. If tariffs extend to generics, the risk is far greater, Caplan added. Unlike brand-name drugs, generic drugs are typically sold at close to the cost they’re made, he said, which makes it difficult for companies to justify the cost of building a new facility. They’d likely be forced to walk away from production or close their plants altogether.Berkeley Lovelace Jr.Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved